){kind=logo}
Loeb & Loeb LLP is pleased to announce that partner Scott Liebman will be speaking at this upcoming conference, presented by World Congress. Learn how to identify risk and improve oversight in pharmaceutical compliance.
With the increasing interest paid by federal agencies to potential statute violations as well as uncertainty with current guidelines, few can afford to overlook potential areas of risk in existing compliance infrastructure and programs. This includes responsibility for all interactions between pharmaceuticals, biotech, medical device, and health care providers, and emerging opportunities for 3rd party commentary via social media platforms.
Listen to industry thought leaders, including Loeb & Loeb's Scott Liebman, discuss emerging risk areas for the compliance infrastructure as well as new techniques in monitoring, auditing, and oversight throughout the workforce to address these risk areas.
With the increasing interest paid by federal agencies to potential statute violations as well as uncertainty with current guidelines, few can afford to overlook potential areas of risk in existing compliance infrastructure and programs. This includes responsibility for all interactions between pharmaceuticals, biotech, medical device, and health care providers, and emerging opportunities for 3rd party commentary via social media platforms.
Listen to industry thought leaders, including Loeb & Loeb's Scott Liebman, discuss emerging risk areas for the compliance infrastructure as well as new techniques in monitoring, auditing, and oversight throughout the workforce to address these risk areas.